Openbookopenbook
Equity
ARQT
+0.0 · +0.00%
USD · NASDAQ

Arcutis Biotherapeutics Inc(ARQT) Stock Analysis | Healthcare

USD --+0.00%
Reward57Moderate
Risk58Medium-High
75%Data
Revenue growing 59% YoY
Profitless Growth
Market Cap:3.15Bn
ⓘ
Reward Rating
57
Moderate
Reward Assessment
75% data coverage
Top 50% of stocksView factors
ⓘ
Risk Rating
58
Medium-High
Risk Assessment
5 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on ARQT to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for ARQT, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $36.88.

What is Arcutis Biotherapeutics Inc?

, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.

ARQT · Verdict

Solid reward · elevated risk

ARQT stands out on balance sheet and growth, but watch the volatility signal.

Based on 88% data coverage

ARQT · Verdict

What’s working & what to watch

Strengths 2

  • Balance sheet76/100

    Current ratio 3.17

  • Growth74/100

    Rev +367.3% CAGR · earnings -62.7%

Watchouts 4

  • Volatility20/100

    Weak vs peers

  • Cash flow26/100

    -2% free-cash-flow margin

  • Profitability42/100

    -4% net margin · 16% ROE

  • Valuation43/100

    P/E 57.1× · PEG 0.26

Model-based scoring. For information only — not financial advice.

What is Arcutis Biotherapeutics Inc?

, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 3.15B, and a P/E ratio of 114.0x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Profitability metrics are mixed — margins may be under pressure.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (57)

The scoring profile indicates moderate reward potential, with growth and momentum as the leading contributors. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

NAMSMid Cap / 3.2B market cap
NewAmsterdam Pharma Company N.V. Ordinary Shares
Compare
ASPHFMid Cap / 3.2B market cap
Ascentage Pharma Group International
Compare
CLDXMid Cap / 3.2B market cap
Celldex Therapeutics Inc
Compare
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap3.15B
P/E Ratio114
Dividend YieldN/A
Beta1.526
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
668,909 shares
$1.7M
0
6-9months
12116,324 shares
$3.1M
0
9-12months
0
0
2 disclosures without share count
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.